Ocuphire Pharma, Inc.

KOL Event on Oral APX3330 for Diabetic Retinopathy and Diabetic Macular Edema

Please join us on October 14th, 2022, 11 AM – 12:00 PM ET for a Key Opinion Leader (KOL) Webinar with Ocuphire Pharma, featuring Peter Kaiser, MD (Cleveland Clinic), Caroline Baumal, MD (Tufts Medical Center), and David Lally, MD (NEW ENGLAND RETINA CONSULTANTS, PC). KOL presentations will lead a discussion on Ocuphire’s APX3330, a novel, first-in-class oral tablet currently in Phase 2b Diabetic Retinopathy and Diabetic Macular Edema. The event will focus on the current treatment landscape and design of the Phase 2b trial, which is expected to read out by the end of 2022.  A live Q&A session will follow.

Register here

Clinical Trials

Current Trials

Recruiting Completed

Study of the Safety and Efficacy of APX3330 in Diabetic Retinopathy ZETA-1: Diabetic Retinopathy Phase 2 Clinical Trial for APX3330

ZETA-1: Diabetic Retinopathy Phase 2 Clinical Trial for APX3330: View Clinical Trial

Completed Trials

Completed

Safety and Efficacy of Ophthalmic Phentolamine Mesylate to Reverse Pharmacologically Induced Mydriasis Reversal of Mydriasis Phase 2 Clinical Trial with Nyxol

Reversal of Mydriasis Phase 2 Clinical Trial with Nyxol: View Clinical Trial

Completed

Safety and Efficacy of Ophthalmic Phentolamine Mesylate in Glaucoma Phase 2 Clinical Trial of Nyxol in Elderly Subjects with Glaucoma

Phase 2 Clinical Trial of Nyxol in Elderly Subjects with Glaucoma: View Clinical Trial

Completed

Single Dose Study of Phentolamine Mesylate Eye Drops in Patients With Severe Night Vision Disturbances Severe Night Vision Disturbance Single-Dose Phase 2 Clinical Trial with Nyxol

Severe Night Vision Disturbance Single-Dose Phase 2 Clinical Trial with Nyxol: View Clinical Trial

Completed

The Safety and Efficacy of Phentolamine Mesylate Ophthalmic Solution in Subjects With Severe Night Vision Disturbances Night Vision Complaints Multiple-Dose Phase 2 Clinical Trial with Nyxol

Night Vision Complaints Clinical Trial: View Clinical Trial

Completed

A Study of APX3330 in Patients With Advanced Solid Tumors APX3330 Cancer Phase 1 Clinical Trial

APX3330 Cancer Phase 1 Clinical Trial: View Clinical Trial

Completed

Nyxol (0.75% Phentolamine Ophthalmic Solution) to Reverse Pharmacologically-Induced Mydriasis in Pediatric Subjects MIRA-4: Nyxol (0.75% Phentolamine Ophthalmic Solution) to Reverse Pharmacologically-Induced Mydriasis in Pediatric Subjects

MIRA-4: Nyxol (0.75% Phentolamine Ophthalmic Solution) to Reverse Pharmacologically-Induced Mydriasis in Pediatric Subjects: View Clinical Trial

Completed

Safety and Efficacy of Nyxol (0.75% Phentolamine Ophthalmic Solution) to Reverse Pharmacologically-Induced Mydriasis (MIRA-3) MIRA-3: A Phase 3 Clinical Trial Evaluating the Safety and Efficacy of Nyxol (0.75% Phentolamine Ophthalmic Solution) to Reverse Pharmacologically-Induced Mydriasis (MIRA-3)

MIRA-3: View Clinical Trial

Completed

Safety and Efficacy of Nyxol (0.75% Phentolamine Ophthalmic Solution) to Reverse Pharmacologically-Induced Mydriasis MIRA-2: Reversal of Mydriasis Phase 3 Clinical Trial for Nyxol

MIRA-2: Reversal of Mydriasis Phase 3 Clinical Trial for Nyxol: View Clinical Trial

Completed

Safety and Efficacy of Nyxol (0.75% Phentolamine Ophthalmic Solution) in Subjects With Dim Light Vision Disturbances LYNX-1: Dim Light Vision Disturbance Phase 3 Clinical Trial for Nyxol

LYNX-1: Dim Light Vision Disturbance Phase 3 Clinical Trial for Nyxol: View Clinical Trial

Completed

Safety and Efficacy of Nyxol With Pilocarpine Eye Drops in Subjects With Presbyopia VEGA-1: Presbyopia Phase 2 Clinical Trial for Nyxol with Low-Dose Pilocarpine

VEGA-1: Presbyopia Phase 2 Clinical Trial for Nyxol with Low-Dose Pilocarpine: View Clinical Trial